Jaguar Animal Health Inc (JAGX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Jaguar Animal Health Inc stock (JAGX) is currently trading at $0.42. Jaguar Animal Health Inc PS ratio (Price-to-Sales) is 0.40. Analyst consensus price target for JAGX is $7.50. WallStSmart rates JAGX as Sell.
- JAGX PE ratio analysis and historical PE chart
- JAGX PS ratio (Price-to-Sales) history and trend
- JAGX intrinsic value — DCF, Graham Number, EPV models
- JAGX stock price prediction 2025 2026 2027 2028 2029 2030
- JAGX fair value vs current price
- JAGX insider transactions and insider buying
- Is JAGX undervalued or overvalued?
- Jaguar Animal Health Inc financial analysis — revenue, earnings, cash flow
- JAGX Piotroski F-Score and Altman Z-Score
- JAGX analyst price target and Smart Rating
Jaguar Animal Health Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Jaguar Animal Health Inc (JAGX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Jaguar Animal Health Inc (JAGX) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading at 1.47x book value, attractively priced
Supporting Valuation Data
Jaguar Animal Health Inc (JAGX) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -0.80%, a shrinking business
Very low institutional interest at 1.44%
Micro-cap company with very limited liquidity and high volatility
Jaguar Animal Health Inc (JAGX) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.40), Price/Book (1.47) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A) suggest expensive pricing. Growth concerns include Revenue Growth at -0.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -411.60%, Operating Margin at -234.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -411.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
JAGX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
JAGX's Price-to-Sales ratio of 0.40x trades at a deep discount to its historical average of 7.11x (36th percentile). The current valuation is 100% below its historical high of 92.66x set in May 2015, and 1230% above its historical low of 0.03x in Feb 2024. Over the past 12 months, the PS ratio has compressed from ~1.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Jaguar Animal Health Inc (JAGX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Jaguar Animal Health Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 12M with 80% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 31% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 80% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Jaguar Animal Health Inc.
Bottom Line
Jaguar Animal Health Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Jaguar Animal Health Inc(JAGX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.